Document Detail

Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
MedLine Citation:
PMID:  884674     Owner:  NLM     Status:  MEDLINE    
The triple combination of 2'-deoxycoformycin (2'-dCF), 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 9-beta-D-arabinofuranosylcytosine was found to be very effective in the therapy of C57BL X DBA/2 F1 mice with intracerebral L1210. At the dosages and dosage scheduling used, the double combination of 2'-dCF and 9-beta-D-arabinofuranosyladenine 5'-phosphate gave minimal but significant increases in life-span. When 9-beta-D-arabinofuranosylcytosine was given at suboptimal dosage to mice with intracerebral L1210, the host toxicity caused by 2'-dCF and 9-beta-D-arabinofuranosyladenine 5'-phosphate in combination was decreased by a factor of 2, allowing a more prolonged therapy. "Cures" were obtained with the triple combination at dosages of 9-beta-D-arabinofuranosylcytosine that did not "cure". The supernatant adenosine deaminase from C57BL X DBA/2 F1 mouse brains was purified and the Ki for 2'-dCF using 9-beta-D-arabinofuranosyladenine as substrate was determined to be not more than 2 X 10(-11) M.
N Caron; S H Lee; A P Kimball
Related Documents :
12669614 - Changing patterns of disease in papua new guinea over a period of 40 years from 1962. p...
25196624 - Isolated contralateral sudden sensorineural hearing loss: an unusual manifestation of p...
10676734 - Cardiopulmonary manifestations of henoch-schönlein purpura.
7085454 - Noniatrogenic rectal tears in three horses.
20199784 - Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfun...
15614334 - Revascularization use and survival outcomes after cardiac catheterization in british co...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  37     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1977 Sep 
Date Detail:
Created Date:  1977-09-29     Completed Date:  1977-09-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  3274-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine Deaminase / antagonists & inhibitors,  metabolism
Antineoplastic Agents / adverse effects,  therapeutic use*
Azepines / therapeutic use*
Body Weight / drug effects
Brain / enzymology
Brain Neoplasms / drug therapy*
Cytarabine / adverse effects,  therapeutic use*
Deoxyribonucleotides / therapeutic use*
Drug Synergism
Drug Therapy, Combination
Leukemia L1210 / drug therapy*
Mice, Inbred DBA
Vidarabine / adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Antineoplastic Agents; 0/Azepines; 0/Deoxyribonucleotides; 147-94-4/Cytarabine; 5536-17-4/Vidarabine; EC Deaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Induction and persistence of pyrimidine dimers in the epidermal DNA of two strains of hairless mice.
Next Document:  Distribution of technetium-99m sulfur colloid in mice bearing melanomas or mammary carcinomas.